you still with us over there in the states Biotechmaster or have...

you still with us over there in the states Biotechmaster or have you finished ramping this puppy. What no more "see you at +$20 by the end of the year" blah blah blah. Your indepth analysis of this stock is greatly missed.

the lasted announcement was not well received getting smashed nearly 22% in the US last night. Being "encouraged" by the results is code for "hmmm could have been better" imo. whilst this small test (37)was primarily focused on the safety of Iluvien i guess the market was not happy that the drug did help the low dose patients to focus! I hope the results of the low dose in the 1000 patient trial is more promising.

whats your thoughts biotech?